Protection against bovine babesiosis with a mixed in vitro culture-derived Babesia bovis and Babesia bigemina vaccine under field challenge. Immunization in a disease-free area

Germinal Jorge Cantó Alarcón; Jesús Antonio Álvarez Martínez; Edmundo Enrique Rojas Ramírez; Juan Alberto Ramos Aragón; Juan Joel Mosqueda Gualito; Carlos Agustín Vega y Murguía; Julio Vicente Figueroa Millán

2003, Number 4

<< Back Next >>

Vet Mex 2003; 34 (4)

Protection against bovine babesiosis with a mixed in vitro culture-derived Babesia bovis and Babesia bigemina vaccine under field challenge. Immunization in a disease-free area

Cantó AGJ, Álvarez MJA, Rojas REE, Ramos AJA, Mosqueda GJJ, Vega y MCA, Figueroa MJV

Full text

How to cite this article

Language: English/Spanish
References: 28
Page: 323-332
PDF size: 98.89 Kb.

ABSTRACT

In Mexico, there is an attenuated live vaccine against bovine babesiosis that has been shown to confer protection to susceptible cattle immunized and challenged under controlled conditions. Immunized cattle survive a challenge using known numbers of virulent parasites of both Babesia bovis and Babesia bigemina. However, stress-inducing field situations such as transportation or tick-transmitted infection have not been taken into account. The objective of this study was to evaluate the protective capacity of the combined vaccine in cattle immunized in a tick-free area and then transported to an endemic area. Ten, 18 month old, susceptible Charolais steers were divided into two groups: one group was immunized with 1 × 107 erythrocytes infected with in vitro culture-derived Babesia bovis and Babesia bigemina parasites; while the second group was immunized with uninfected bovine erythrocytes. Two months later, both groups were transferred to a bovine babesiosis endemic area and allocated in a corral infested with Babesia-infected Boophilus microplus ticks. Animals remained there for the rest of the experiment and never received ixodicide treatment. Eighteen days post-allocation, all five control animals presented with severe clinical signs characteristic of acute bovine babesiosis, including a rectal temperature (RT) greater than 40.5oC for several days and a decreased packed cell volume (PCV) of 48%. Both protozoan species were found in blood smears and all animals in the control group had to be treated in order to avoid their demise. The immunized cattle also presented both Babesia species in peripheral blood samples, increased RT and a 37% PCV reduction, but remained in good corporal condition and did not require treatment. This study shows the protective capacity conferred to cattle by the combined vaccine when immunized in a Babesia-free area and then transported to an endemic area.

REFERENCES

Connaway JW, Frances M. Texas Fever. Amissori Agric Exp Sta Bull 1899;48:1-5.
2. Callow LL. Tick-borne livestock disease and their vectors. Australian methods of vaccination against anaplasmosis and babesiosis. Wild Anim Rev 1976;18:9-15.
3. Callow LL, Mellors LT. A new vaccine for Babesia argentina infection prepared in splenectomized cattle. Aust Vet J 1966;42:464-470.
4. Nari A, Solari MA, Gradizo H. Hemovacuna para el control de Babesia spp y Anaplasma marginale en Uruguay. Veterinaria 1979;15:137-147.
5. Brizuela CM, Ortellado CA, Sanabria E, Torres O, Ortigosa D. The safety and efficacy of Australian tick-borne disease vaccine strains in cattle in Paraguay. Vet Parasitol 1998;76:27-41.
6. Alonso M, Fadrada M, Blandino T, Gómez E, Baudín C. Atenuación de una cepa cubana de Babesia bovis con fines inmunoprofilácticos. Rev Salud Anim 1991;13:81-88.
7. Rogers RJ, Dimmock CK, De Vos AJ, Rodwen BJ. Bovine leucosis virus contamination of vaccine produced in vivo against bovine babesiosis and anaplasmosis. Aust Vet J 1988;65:285-290.
8. Rodriguez SD, Buening GM, Green TJ, Carson CA. Cloning of Babesia bovis by in vitro cultivation. Infect Immun 1983;42:15-19.
9. Vega CA, Buening GM, Green TJ, Carson CA. In vitro cultivation of Babesia bigemina. Am J Vet Res 1985;46:416-420.
10. Scheffers TP, Montenegro-James S. Vaccines against babesiosis using soluble parasite antigen. Parasitol Today 1995;11:456-462.
11. James MA, Levy MG, Ristic M. Isolation and partial characterization of culture-derived soluble Babesia bovis antigens. Infect Immun 1981;31:358-361.
12. Smith RD, Carpenter J, Cabrera A, Gravely SM, Erp EE, Osorno MB, et al. Bovine Babesiosis: vaccination against tick-borne challenge exposure with culture-derived Babesia bovis immunogens. Am J Vet Res 1979;40:1678-1682.
13. Echaide IE, de Echaide ST, Guglielmone AA. Live and soluble antigens for cattle protection to Babesia bigemina. Vet Parasitol 1993;51:35-40.
14. Carcy B, Precigout E, Vaventin A, Gorenflot A, Schrevel J. A 37-kilodalton glycoprotein of Babesia divergens is a major component of a protective fraction containing low molecular mass culture-derived exoantigens. Infect Immun 1995;63:811-817.
15. Allred DR, Cinque RM, Lane TJ, Ahrens KP. Antigenic variation of parasite-derived antigens on the surface of Babesia bovis infected erythrocyte surface. Infect Immun 1994;62:91-98.
16. Hines SA, Palmer GH, Jasmer DP, Goff WL, McElwain TF. Immunization of cattle with recombinant Babesia bovis merozoite surface antigen-1. Infect Immun 1995;63:349-352.
17. Wright IG, Casu R, Commins MA, Dalrymple BP, Gale KR, Goodger BV, et al. The development of a recombinant Babesia vaccine. Vet Parasitol 1998;44:3-13.
18. Dalrymple BP. Molecular variation and diversity in candidate vaccine antigens from Babesia Acta Trop 1993;53:227-238.
19. Cantó GJ, Figueroa JV, Alvarez JA, Ramos JA, Vega CA. Capacidad inmunoprotectora de una clona irradiada de Babesia bovis derivada de cultivo in vitro. Tec Pecu Mex 1996;34:127-134.
20. Figueroa JV, Cantó GJ, Álvarez JA, Lona GR, Ramos JA, Vega CA. Capacidad protectora de una cepa de Babesia bigemina derivada de cultivo in vitro. Tec Pecu Mex 1998;36:95-101.
21. Cantó GJ, Figueroa JV, Ramos JA, Álvarez JA, Mosqueda JJ, Vega CA. Evaluación de la patogenicidad y capacidad protectora de un inmunógeno fresco combinado de Babesia bigemina y Babesia bovis. Vet Mex 1999;30:215-220.
22. Cantó GJ, Ramos JA, Rojas EE, Vega CA, Oviedo V, Figueroa JV, et al. Evaluación de la inocuidad y protección de un inmunógeno derivado de cultivo in vitro de Babesia bovis y Babesia bigemina multiplicado en bovinos. Tec Pecu Mex 2002;40:127-138.
23. Goldman M, Pipano E, Rosenberg AS, Fluorescent antibody tests for Babesia bigemina y Babesia berbera. Res Vet Sci 1972;13:77-82.
24. Friedhoff KT, Smith RD. Transmission of Babesia by ticks. In: Ristic M, Kreier JP, editors Babesiosis. New York: Academic Press 1981:267-321
25. Buening GM, Kuttler KL, Rodríguez SD. Evaluation of a cloned Babesia bovis organism as a live immunogen. Vet Parasitol 1986;22:235-241.
26. Bock RE, de Vos AJ, Kingston TG, Shields IA, Dalgliesh RJ. Investigations of breakdowns in protection provided by living Babesia bovis vaccine. Vet Parasitol 1992;43:45-49.
27. Mahoney DF. The immune response to babesiosis. In: Morrison WL editor The ruminant immune system in health and disease. Cambridge: Cambridge University Press 1986:539-545.
28. Brown WC, Palmer GH. Designing blood stage vaccines against Babesia bovis and Babesia bigemina. Parasitol Today 1999;7:275-281.